A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy
Blood Purification · 18.07.2024 · 53 (10) · 838-846
DOI: 10.1159/000540302 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Blood Purification, online erschienen am 18.07.2024. Verfasst von Esha Sondhi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Critical Care, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, UPMC Children's Hospital of P…. Hauptthemen laut MEDLINE: Anticoagulants, Epoprostenol, Heparin, Citric Acid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NICHD NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Anticoagulants are used in continuous renal replacement therapy (CRRT) to prolong filter life. There are no prior investigations directly comparing epoprostenol to more commonly used forms of anticoagulation in children. Therefore, the primary aim of this study was to assess the efficacy and safety of epoprostenol as compared to heparin and citrate anticoagulation in a pediatric cohort.
Methods
We performed a retrospective analysis of all patients <18 years of age admitted to an academic quaternary care children’s hospital from 2017–2022 who received epoprostenol, heparin, or citrate exclusively for CRRT anticoagulation. Efficacy was evaluated by comparing the hours to the first unintended filter change and the ratio of filters used to CRRT days. Safety was assessed by evaluating changes in platelet count and vasoactive-ionotropic score (VIS).
Results
Of 101 patients, 44 received epoprostenol (43.6%), 38 received heparin (37.6%), and 19 received citrate (18.8%). The first filter change was more commonly planned in patients receiving anticoagulation with epoprostenol (43%) as compared to citrate (11%) or heparin (29%) (p = 0.034). Of those patients where the first filter change was unintended (n = 33), there were greater median hours until the filter was replaced in those receiving epoprostenol (29) when compared to citrate (21) (p = 0.002) or heparin (18) (p = 0.003). There was a smaller median ratio of filters used to days on therapy in the patients that received epoprostenol (0.53) when compared to citrate (1) (p = 0.003) or heparin (0.75) (p = 0.001). For those receiving epoprostenol, there was no significant decrease in platelet count when comparing values prior to CRRT initiation through 7 days of therapy. There was no significant difference in VIS when comparing values prior to CRRT initiation through the first 2 days of CRRT.
Conclusions
Epoprostenol-based anticoagulation is effective when compared to other anticoagulation strategies used in pediatric CRRT with a favorable side effect profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Critical Care, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Pediatric CRRT Program, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Safar Center Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Epidemiology, Epidemiology Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Förderung
- NIDDK NIH HHS
- NICHD NIH HHS
Zitieren
APA
Sondhi, E., Stewart, M., Harper, J., Konyk, L., McSteen, C., Crowley, K. L., Kim-Campbell, N., Fabio, A., & Fuhrman, D. Y. (2024). A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy. Blood Purification, 53(10), 838-846. https://doi.org/10.1159/000540302
Vancouver
Sondhi E, Stewart M, Harper J, Konyk L, McSteen C, Crowley KL, et al. A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy. Blood Purification. 2024;53(10):838-846. doi:10.1159/000540302
BibTeX
@article{Sondhi2024,
author = {Sondhi, Esha and Stewart, Martha and Harper, Jenna and Konyk, Leslie and McSteen, Coleen and Crowley, Kelli L and Kim-Campbell, Nahmah and Fabio, Anthony and Fuhrman, Dana Y},
title = {A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy},
journal = {Blood Purification},
year = {2024},
volume = {53},
number = {10},
pages = {838--846},
doi = {10.1159/000540302}
}
EUVIMED